GC Medical Science

녹십자엠에스 · 142280

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$63.4M (₩87.5B)

Overview

GC Medical Science makes diagnostic reagents used to detect diseases such as HIV, hepatitis, tuberculosis, and malaria, as well as blood-glucose monitoring devices for diabetes management and dialysis fluids used in treating patients with chronic kidney failure.

Its products are supplied to hospitals, clinics, public health centres, and medical wholesale distributors across Korea. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the majority of its revenue from its diagnostic-reagent division, which spans immune, biochemical, and molecular diagnostics.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$78.6M

▲ +4.4% YoY

Operating profit · FY2025

US$2.1M

▲ +23.7% YoY

Net income · FY2025

US$2.5M

▲ +1.9% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$68.1M(₩94B)	US$75.3M(₩103.9B)	US$78.6M(₩108.4B)
Operating profit	US$1.3M(₩1.8B)	US$1.7M(₩2.3B)	US$2.1M(₩2.9B)
Net income	US$1.4M(₩1.9B)	US$2.5M(₩3.4B)	US$2.5M(₩3.5B)

Revenue

FY2023US$68.1M
FY2024US$75.3M
FY2025US$78.6M

Operating profit

FY2023US$1.3M
FY2024US$1.7M
FY2025US$2.1M

Net income

FY2023US$1.4M
FY2024US$2.5M
FY2025US$2.5M

Key ratios (FY2025)

ROE

7.5%

Debt/Eq

95.2%

Op. margin

2.7%

Net margin

3.2%

Rev. YoY

▲ +4.4%

Why it matters

The company distributes diagnostic reagents from global partners including Germany's Diasys alongside its own products, broadening its portfolio beyond what most domestic peers offer.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?